ARF peptide (1-22) [ARF_HUMAN, 1-22], 1027629-94-2

ARF peptide (1-22) [ARF_HUMAN, 1-22], 1027629-94-2 (Uniprot: Q8N726) is a peptide from alternative frame (ARF) tumour suppressor protein for cancer-targeting research. The ARF peptide (1-22) [ARF_HUMAN, 1-22], 1027629-94-2 peptide, H-MVRRFLVTLRIRRACGPPRVRV-OH from JPT is produced under strict quality control and quality management.

ARF peptide (1-22) [ARF_HUMAN, 1-22], 1027629-94-2 - Specifications

• Peptide sequence: H-MVRRFLVTLRIRRACGPPRVRV-OH
• Amount: 1 mg
• Purity: > 90% (HPLC/MS)
• Counterion: TFA
• Delivery Format: Freeze-dried in plastic vial
• Application(s): Cancer research
• Condition(s)/Topic(s): Cancer
• Standard Delivery Time: approx. 3 weeks

Non-RGD Cancer Peptides from JPT

Cancer peptides are widely used to develop targeted diagnostic and therapeutic approaches. They offer different functionalities such as binding tumor-associated receptors, interacting with cellular membranes, or interfering with tumor microenvironment. Depending on the application, these mechanisms enable specific delivery, tumor imaging, and tumor cell killing with low side effects.
JPT offers a wide portfolio of high-quality cancer peptides engineered for robust and reproducible research in oncology including RGD and non-RGD cancer peptides.

Benefits of JPT’s Non-RGD Cancer Peptides

• Each peptide quality controlled and guaranteed for identity and purity
• CoA and HPLC-MS data available
• High batch-to-batch consistency
• Synthesis protocols designed to avoid toxic contaminants and side products
• Provision of freeze dried aliquots for enhanced stability
• Proven track record for applications in clinical studies